Background: Solid organ recipients are at an increased risk of developing various malignancies. We investigated the incidence, clinical features, and outcome of patients diagnosed with head and neck cancer after organ transplantation.
Methods: A retrospective analysis was undertaken of patients who underwent solid organ transplantation (kidney, liver, lung, heart) treated at our institution from 1992 to 2010.
Results: Of 2817 organ recipients, 175 patients (6.1%) developed 391 head and neck malignancies. Cutaneous malignancies were the most common (93%): squamous cell carcinoma (SCC; 51%) and basal cell carcinoma (BCC; 42%). The average interval from transplantation to diagnosis of head and neck malignancy was 7.3 years, with liver recipients diagnosed earlier. Eighteen percent of patients presented with an aggressive pattern of head and neck cancer, including 24% of patients with cutaneous SCC.
Conclusion: Organ transplantation recipients are at a higher risk to develop head and neck cancer with an aggressive behavior characterized by multiple recurrences and decreased survival.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/hed.23283 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effect of dupilumab on otitis media associated with eosinophilic chronic rhinosinusitis.
Braz J Otorhinolaryngol
January 2025
Tokushima University Graduate School, Institute of Biomedical Sciences, Department of Otolaryngology-Head and Neck Surgery, Tokushima, Japan.
Objective: Eosinophilic Otitis Media (EOM) is an intractable disease caused by type 2 inflammation, such as Eosinophilic Chronic Rhinosinusitis (ECRS) and bronchial asthma. Biologics have recently been used to treat ECRS and bronchial asthma. Biologics are not indicated for EOM; however, because approximately 10% of ECRS cases has concomitant EOM, concomitant EOM improvement has been observed when dupilumab is administered for ECRS.
View Article and Find Full Text PDFNovel Use of Drug-eluting Stent in Otologic Surgery to Prevent Restenosis.
Ann Otol Rhinol Laryngol
January 2025
Department of Otolaryngology-Head and Neck Surgery, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
Objectives: The primary objective of this case series is to assess the effectiveness of the off-label use of the PROPEL drug-eluting stent, traditionally FDA-approved for sinus surgery, in preventing restenosis following canalplasty in patients with chronic otologic conditions or congenital anomalies. The stent provides both mechanical support to maintain canal patency and localized steroid delivery to reduce inflammation and scarring.
Methods: Four patients with various otologic conditions underwent canalplasty, followed by the placement of drug-eluting stents into the external auditory canal.
Lymph Node Yield/Ratio, Neutrophil-Lymphocyte Ratio: Prognostic Factors in cN0 Laryngeal Carcinoma.
Laryngoscope
January 2025
Department of Otolaryngology - Head and Neck Surgery, Mansoura University, Mansoura, Egypt.
Objectives: The aim of this study was to investigate the role of lymph node yield (LNY), lymph node ratio (LNR), and neutrophil to lymphocyte ratio (NLR) as prognostic factors, their impact on survival in patients with advanced laryngeal squamous cell carcinoma (LSCC).
Methods: This multicentric retrospective study included 195 patients with clinical N0 advanced laryngeal carcinoma who underwent total laryngectomy and/or total pharyngolaryngectomy over 5 years. The number of lymph nodes extracted (LNY) and the number of positive nodes were counted.
Correction of Lower Lip Malposition With Fascia Lata Slings Following Anterior Mandibular Resection.
Laryngoscope
January 2025
Plastic & Reconstructive Surgery Service, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
Lower lip malposition can occur after anterior mandibular resection as a result of the loss of soft tissue lip attachments. We report our technique of cranial suspension of the lower lip with fascia lata slings to improve lip position. Correction of lip ptosis results in cessation of drooling, improved oral intake, and restoration of facial aesthetics.
View Article and Find Full Text PDFThe present and future of digital health, digital medicine, and digital therapeutics for allergic diseases.
Clin Transl Allergy
January 2025
Department of Otorhinolaryngology & Clinical Allergy Center, The First Affiliated Hospital, Nanjing Medical University, Nanjing, China.
Background: Digital health, digital medicine, and digital therapeutics integrate advanced computer technologies into healthcare, aiming to improve efficiency and patient outcomes. These technologies offer innovative solutions for the management of allergic diseases, which affect a significant proportion of the global population and are increasing in prevalence. BODY: This review examines the current progress and future potential of digital health in allergic disease management.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!